Why the study?
The success rate of traditional radiofrequency ablation methods for AF remains less than ideal, prompting refinements such as high-power short-duration ablation to improve efficacy, efficiency, and lesion durability.
Does high-power short-duration (HPSD) radiofrequency ablation improve procedural efficiency and clinical outcomes compared to low-power long-duration (LPLD) ablation in patients with paroxysmal and persistent atrial fibrillation?
Does high-power short-duration (HPSD) radiofrequency ablation improve procedural efficiency and clinical outcomes compared to low-power long-duration (LPLD) ablation in patients with paroxysmal and persistent atrial fibrillation?
HPSD ablation is a safe and effective strategy for atrial fibrillation that improves procedural efficiency and lesion durability compared to traditional LPLD ablation.
May support HPSD for efficient AF ablation; leaves open need for RCTs before practice change.
Catheter ablation has become a cornerstone in atrial fibrillation (AF) therapy, improving freedom from all-atrial arrhythmias, as well as outperforming antiarrhythmic drugs in alleviating AF-related symptoms, reducing hospitalizations, and enhancing quality of life. Nevertheless, the success rate of traditional radiofrequency ablation (RFA) methods remains less than ideal. To address these issues, refinement in RFA strategies has been developed to improve efficacy and laboratory efficiency during pulmonary vein isolation (PVI). High-power short-duration (HPSD) RFA has emerged as a safe strategy to reduce the time required to produce durable lesions. This article reviews critical aspects of HPSD ablation in the management of both paroxysmal and persistent AF, covering aspects such as effectiveness, safety, procedural intricacies, and the underlying biophysics.
No takes yet. Share an insight, caveat, or question.
Hoyos et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: